STOCK TITAN

Aptose Biosciences, Inc. - APTO STOCK NEWS

Welcome to our dedicated news page for Aptose Biosciences (Ticker: APTO), a resource for investors and traders seeking the latest updates and insights on Aptose Biosciences.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Aptose Biosciences's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Aptose Biosciences's position in the market.

Rhea-AI Summary
Aptose Biosciences Inc. will provide a clinical update on October 30, 2023, regarding its lead compound tuspetinib, a precision targeted myeloid kinase inhibitor for the treatment of acute myeloid leukemia (AML). The update will include up-to-date clinical data and will be presented by Dr. Naval Daver, the lead investigator on Aptose's APTIVATE trial.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.76%
Tags
none
-
Rhea-AI Summary
Aptose Biosciences to participate in Cantor Global Healthcare Conference. Recent clinical data shows positive responses to tuspetinib in AML patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.17%
Tags
conferences
-
Rhea-AI Summary
Aptose Biosciences announces $3 million investment from Hanmi Pharmaceutical for its lead hematology drug, tuspetinib, in the APTIVATE trial for relapsed or refractory acute myeloid leukemia (R/R AML). Second tranche of investment up to $4 million pending achievement of milestones. Tuspetinib shows promise in combination with venetoclax.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.19%
Tags
none
Rhea-AI Summary
Aptose Biosciences to participate in H.C. Wainwright conference; positive clinical data for tuspetinib in AML patients
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.45%
Tags
conferences
-
Rhea-AI Summary
Aptose Biosciences Inc. (APTO) announces a 50% CRc response rate with Tuspetinib/Venetoclax doublet in evaluable patients, along with CRc percentages in patients who failed prior Venetoclax and in patients with wildtype and mutated FLT3. Hanmi Pharmaceutical commits investment in Aptose up to 19.99% ownership or $7 million. Financial results for the three months ended June 30, 2023, and corporate update revealed. Key corporate highlights include the APTIVATE Phase 1/2 clinical trial of tuspetinib, equity investments in Aptose, and a successful Type B EOP1 meeting with US FDA. Financial results of operations and research and development expenses were also detailed.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.75%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.28%
Tags
conferences earnings
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.99%
Tags
none
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary
Aptose Biosciences will provide a clinical update on June 10th regarding their lead compound tuspetinib, a myeloid kinase inhibitor, currently being tested in the APTIVATE trial. The update will include insights from the completed Phase 1/2 trial and early trends from the ongoing trial. Tuspetinib has shown potential as a single agent and in combination with venetoclax for treating acute myeloid leukemia (AML).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.38%
Tags
none
Aptose Biosciences, Inc.

Nasdaq:APTO

APTO Rankings

APTO Stock Data

19.02M
12.52M
19.71%
7.63%
0.54%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
United States of America
TORONTO

About APTO

aptose biosciences is a science-driven biotechnology company advancing first-in-class agents to treat life-threatening cancers, such as acute myeloid leukemia (aml), high-risk myelodysplastic syndromes (mds) and other hematologic malignancies. based on insights into the genetic and epigenetic profiles of certain cancers and patient populations, aptose is building a pipeline of novel oncology therapies directed at dysregulated processes and signaling pathways. aptose is developing targeted medicines for precision treatment of these diseases, based on a patient’s specific gene expression signature. in the treatment of cancer, this strategy is intended to optimize efficacy and quality of life by minimizing the cytotoxic side effects associated with conventional therapies. cg026806 (cg’806) is a highly potent first-in-class pan-flt3/btk inhibitor. this small molecule therapeutic agent, exhibits a picomolar ic50 toward the fms-like tyrosine kinase 3 with the internal tandem duplication (flt